Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks close lower on UK deflation, weak Chinese trade data

Tue, 13th Oct 2015 16:12

(ShareCast News) - The FTSE 100 ended down 28.90 points to 6,342.28 on Tuesday as September data showed the UK experienced deflation and China's exports and imports declined.The Office for National Statistics said the UK consumer price index fell 0.1% year-on-year last month, compared to analysts' estimates for a flat reading in line with August.On a month-on-month comparison, CPI also dropped 0.1% in September following a 0.2% increase in August. Analysts had predicted 0% growth.The main driver of deflation was discounting at clothing stores and falling petrol and diesel prices."As UK year-on-year inflation hit negative territory for only the second time since 1960, the impact of persistent disinflation upon Bank of England decision making will no doubt have been playing into traders mind-sets, sending GBP-USD 130 points lower within two hours," said IG market analyst Joshua Mahony."However, it is also worth bearing in mind that with wages growing at the fastest rate in over a decade, this is a benefit for the consumer and helps make up for all those years where real wages fell repeatedly."Chinese tradeChinese exports decreased 3.7% in September from a year earlier in US dollar terms following a 5.5% drop in August, the General Administration of Customs revealed. Analysts had expected a 6% slide.Imports plunged 20.4% last month, worse than the 15.9% dip predicted, after a 13.8% fall in August.The trade balance, however, unexpectedly widened to $60.34bn in September from $60.24bn a month earlier when a surplus of $47.90bn had been forecast."Chinese trade figures have been a source of concern for some time now, with both dollar-denominated exports and imports having contracted for most of the year when compared to 12 months previous," said Craig Erlam, senior market analyst at Oanda."The biggest concern is the huge decline in imports and while a large part of this can be attributed to the collapse in commodity prices and should therefore ease of in the coming months, there does also appear to be a domestic demand problem as well."McCafferty calls for rate riseBoE policymaker Ian McCafferty has reiterated that interest rates need to rise to allow more scope for cuts in the event of a financial crisis.In a testimony to the Treasury Committee on the hearing of McCafferty's reappointment to the Monetary Policy Committee on Tuesday, he said there was a need to return the Bank Rate far enough above zero "to a level at which it can be an effective instrument" in tightening or loosening policy. Last Thursday, McCafferty voted in favour of raising interest rates to 0.75% from 0.50%. He was once again the only policymaker to recommend the move.Royal Mail tops FTSE fallersRoyal Mail was in the red on news the government has sold its remaining stake in the postal service group to professional investors.Luxury fashion retailer Burberry was under the cosh amid renewed worries about China - to which it is heavily exposed - following disappointing trade figures.Barclays edged lower on reports the bank may name US investment banker Jes Stanley as its new chief executive.Going the other way, SABMiller jumped after the brewer agreed to a £68bn takeover offer from AB InBev.Housebuilders rallied in line with FTSE 250 peer Bellway which gained after posting a 44% jump in full-year profits that beat expectations. Persimmon, Barratt Developments and Taylor Wimpey were both firmly in the black.Pharmaceuticals giant GlaxoSmithKline was also on the front foot after JPMorgan Cazenove upgraded the stock to 'neutral' from 'underweight' and lifted the price target to 1,370p from 1,320p. The bank noted that medium-term consensus earnings per share estimates have fallen 15-18% year-to-date and expectations now look achievable, with downgrades no longer a concern. Market MoverstechMARK 3,034.34 -0.00%FTSE 100 6,341.41 -0.47%FTSE 250 16,902.78 -0.50% FTSE 100 - RisersSABMiller (SAB) 3,949.50p +9.06%GlaxoSmithKline (GSK) 1,328.50p +1.72%Persimmon (PSN) 1,967.00p +1.60%Carnival (CCL) 3,384.00p +1.50%Inmarsat (ISAT) 929.00p +1.42%Berkeley Group Holdings (The) (BKG) 3,250.00p +1.25%International Consolidated Airlines Group SA (CDI) (IAG) 577.00p +1.23%Barratt Developments (BDEV) 633.50p +1.20%easyJet (EZJ) 1,725.00p +1.17%Taylor Wimpey (TW.) 192.70p +1.05% FTSE 100 - FallersRoyal Mail (RMG) 453.30p -4.00%Tesco (TSCO) 194.30p -3.74%G4S (GFS) 248.20p -3.27%Burberry Group (BRBY) 1,427.00p -3.25%Aberdeen Asset Management (ADN) 333.80p -3.11%Standard Chartered (STAN) 739.40p -3.05%Johnson Matthey (JMAT) 2,520.00p -2.85%Sainsbury (J) (SBRY) 263.80p -2.73%Old Mutual (OML) 205.30p -2.61%Glencore (GLEN) 118.00p -2.60% FTSE 250 - RisersMichael Page International (MPI) 483.50p +4.16%Bellway (BWY) 2,453.00p +3.50%Spire Healthcare Group (SPI) 368.30p +3.40%Sophos Group (SOPH) 231.90p +3.25%Auto Trader Group (AUTO) 330.00p +2.96%Crest Nicholson Holdings (CRST) 540.50p +2.85%Virgin Money Holdings (UK) (VM.) 399.90p +2.51%BTG (BTG) 573.00p +2.32%CLS Holdings (CLI) 1,790.00p +2.11%Vectura Group (VEC) 165.10p +2.10% FTSE 250 - FallersKaz Minerals (KAZ) 135.40p -6.30%Evraz (EVR) 89.20p -5.56%Weir Group (WEIR) 1,284.00p -4.75%IMI (IMI) 1,012.00p -4.17%Vedanta Resources (VED) 578.50p -4.14%Rotork (ROR) 179.10p -3.92%Home Retail Group (HOME) 144.60p -3.73%Homeserve (HSV) 411.00p -3.54%Bodycote (BOY) 556.50p -3.30%Ashmore Group (ASHM) 282.50p -3.19% FTSE TechMARK - RisersNCC Group (NCC) 260.00p +4.00%Dialight (DIA) 664.00p +1.37%Oxford Biomedica (OXB) 7.38p +1.37%Triad Group (TRD) 31.50p +0.80%Gresham Computing (GHT) 110.50p +0.45%Skyepharma (SKP) 337.25p +0.30% FTSE TechMARK - FallersSarossa (SARS) 1.82p -4.71%SDL (SDL) 383.75p -4.06%Spirent Communications (SPT) 73.25p -2.98%Oxford Instruments (OXIG) 677.00p -0.73%Innovation Group (TIG) 39.50p -0.63%BATM Advanced Communications Ltd. (BVC) 19.75p -0.63%E2V Technologies (E2V) 235.50p -0.63%XP Power Ltd. (DI) (XPP) 1,505.00p -0.33%Ricardo (RCDO) 902.00p -0.28%KCOM Group (KCOM) 90.75p -0.27%
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.